8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
8 位分析师评估细胞内疗法：你需要知道的
During the last three months, 8 analysts shared their evaluations of Intra-Cellular Therapies (NASDAQ:ITCI), revealing diverse outlooks from bullish to bearish.
在过去的三个月中，8位分析师分享了他们对细胞内疗法（纳斯达克股票代码：ITCI）的评估，揭示了从看涨到看跌的不同前景。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他们最近的评级，简要介绍了过去30天中不断变化的情绪，并将其与前几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $85.88, a high estimate of $101.00, and a low estimate of $64.00. Surpassing the previous average price target of $76.75, the current average has increased by 11.9%.
分析师分析的12个月目标股价提供了见解，平均目标股价为85.88美元，最高估计为101.00美元，低估值为64.00美元。超过了之前的平均目标股价76.75美元，目前的平均价格上涨了11.9％。
Investigating Analyst Ratings: An Elaborate Study
调查分析师评级：一项详尽的研究
In examining recent analyst actions, we gain insights into how financial...
在研究分析师最近的行为...
登录免费看全文
登录/注册